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Letter
Response to the letter to the 
editor by Hafer and Johnson 
concerning ‘Mechanism of 
action of HTX-011: a novel, 
extended- release, dual- acting 
local anesthetic formulation for 
postoperative pain’
To the Editor
We appreciate the comments provided 
by Hafer and Johnson1 regarding our 
recent manuscript.2 Their primary 
concern appears to be the clinical evidence 
supporting the analgesic properties of 
HTX-011 beyond 24 hours.
HTX-011 is a dual- acting local anes-
thetic consisting of bupivacaine and low- 
dose meloxicam in an extended- release 
polymer. Preclinical data demonstrated 
that meloxicam normalized the local pH 
at the surgical site and synergistically 
potentiated the magnitude and duration 
of analgesic activity of bupivacaine in a 
pig postoperative pain model through 
72 hours. The early proof- of- concept 
phase II bunionectomy study presented in 
our manuscript2 confirmed the preclinical 
findings and demonstrated that HTX-011 
resulted in greater pain reduction than 
either extended- release bupivacaine or 
extended- release meloxicam through 
72 hours following surgery. Moreover, 
HTX-011 significantly reduced mean 
pain intensity 24 to 72 hours post surgery 
when compared with extended- release 
bupivacaine (area under the concentra-
tion time curve (AUC)24-72, 252.2 vs 312.3, 
p=0.0156), validating that meloxicam 
does indeed potentiate the effect of bupi-
vacaine in HTX-011 beyond the first 
24 hours.
Drs. Hafer and Johnson suggest that 
further investigation is needed to vali-
date the clinical efficacy of HTX-011 
beyond 24 hours.1 Two published phase III 
studies (EPOCH-1 (bunionectomy) and 
EPOCH-2 (herniorrhaphy))3 4 provide 
such evidence. In EPOCH-1, HTX-011 
demonstrated a significant reduction 
in mean pain intensity over 72 hours 
(AUC0-72) compared with saline placebo 
(p<0.0001) and bupivacaine HCl 
(p=0.0002).3 Importantly, the analgesic 
benefit continued beyond 24 hours as 
HTX-011 demonstrated significantly 
lower mean pain scores from 24 to 
72 hours (AUC24-72) compared with saline 
placebo (p<0.0001) and bupivacaine HCl 
(p=0.0072)3 (table 1), confirming that 
the efficacy observed through 72 hours 
was not merely a carry- over from the effi-
cacy observed in the first 24 hours. Similar 
results were observed in EPOCH-2, 
with HTX-011 providing superior pain 
reduction compared with saline placebo 
and bupivacaine HCl through 72 hours 
(both p<0.001) and specifically from 24 
to 72 hours (p=0.0264 and p=0.0007, 
respectively), again confirming that 
HTX-011 continues to provide sustained 
and superior analgesia beyond the first 
24 hours.4
The beneficial effects of HTX-011 on 
opioid reduction were also confirmed to 
persist beyond 24 hours in the phase III 
studies. In both studies, HTX-011 signifi-
cantly reduced opioid consumption and 
enabled significantly more patients to 
recover without requiring any opioids 
(opioid- free) throughout the 72 hours 
postoperative period compared with 
both saline placebo and bupivacaine 
HCl (p values ranging from p<0.001 to 
p<0.05).3 4 In EPOCH-1, HTX-011 
treatment reduced opioid consumption 



















AUC0-24 of the NRS pain intensity scores
  Mean (SD) 155.8 (48.49) 131.4 (48.86) 98.7 (59.55) 143.8 (54.94) 126.7 (52.68) 97.7 (60.31)
  P value vs saline placebo 0.0004 <0.0001 0.0238 <0.0001
  P value vs bupivacaine HCl <0.0001 <0.0001
AUC24-72 of the NRS pain intensity scores
  Mean (SD) 289.6 (115.64) 262.1 (117.25) 224.6 (131.28) 207.1 (122.32) 215.2 (111.97) 171.7 (120.40)
  P value vs saline placebo 0.0806 <0.0001 0.6041 0.0264
  P value vs bupivacaine HCl 0.0072 0.0007
Opioid use
Opioid consumption from 0 to 24 hours (MME)
  Mean (SD) 14.1 (8.58) 11.8 (9.39) 7.4 (7.82) 11.7 (10.82) 7.3 (8.61) 5.2 (7.86)
  Median (min, max) 14.0 (0.0 to 45.0) 10.0 (0.0 to 44.0) 5.0 (0.0 to 29.0) 9.8 (0.0 to 37.0) 5.0 (0.0 to 37.0) 0.0 (0.0 to 35.0)
  P value vs saline placebo <0.0001 <0.0001
  P value vs bupivacaine HCl <0.0001 0.0073
Opioid consumption from 24 to 72 hours (MME)
  Mean (SD) 15.9 (14.77) 13.3 (14.56) 11.4 (13.64) 5.9 (9.30) 7.2 (11.10) 5.62 (11.09)
  Median (min, max) 12.5 (0.0 to 60.0) 8.0 (0.0 to 57.0) 5.0 (0.0 to 54.0) 0.0 (0.0 to 37.0) 0.0 (0.0 to 69.0) 0.0 (0.0 to 68.0)
  P value vs saline placebo 0.0024 0.2532
  P value vs bupivacaine HCl 0.1585 0.0161
Opioid- free
  % patients opioid- free through 72 hours 2% 11% 29% 22% 40% 51%
  P value vs saline placebo <0.0001 <0.0001
  P value vs bupivacaine HCl 0.0001 0.0486
AUC, area under the concentration time curve; MME, morphine milligram equivalents; NRS, numeric rating scale.
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by 48% versus saline placebo and by 
37% versus bupivacaine HCl over the 
first 24 hours following surgery (both 
p<0.0001; table 1).5 Efficacy extended 
beyond 24 hours as HTX-011 signifi-
cantly reduced opioid use between 
24 and 72 hours versus saline placebo 
(p=0.0024), and decreased opioid use 
versus bupivacaine HCl.5 In EPOCH-2, 
HTX-011 significantly reduced opioid 
use during the first 24 hours (p<0.0001 vs 
saline placebo, p=0.0073 vs bupivacaine 
HCl), with continued reduction between 
24 and 72 hours versus bupivacaine HCl 
(p=0.0161).5
These phase III studies confirm that 
HTX-011 provides sustained and supe-
rior analgesic efficacy throughout the 
72 hour postoperative period with signifi-
cantly lower pain scores, reduced opioid 
consumption, and more opioid- free 
patients compared to placebo and bupi-
vacaine HCl. Together, the preclinical 
and clinical data support the mechanism 
of action (MOA) put forth in our publi-
cation.2 In addition, our proposed MOA 
is consistent with the established phenom-
enon of acidic pH limiting the duration 
of action of local anesthetics.6 7 We hope 
the consistent clinical efficacy observed 
across several studies, including in the 24 
to 72 hours window, reassures Drs. Hafer 
and Johnson, along with their colleagues, 
of the 72 hours duration of action of 
HTX-011.
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